These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18790198)

  • 1. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
    Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
    Baez Y; Giron F; Niño-Murcia A; Rodríguez J; Salcedo S
    Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.
    Yuan-Xin L; Ning L; You-Sheng L; Xiao-Dong N; Ming L; Jian W; Jie-Shou L
    Transplant Proc; 2010; 42(1):29-34. PubMed ID: 20172275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience.
    Tan HP; Donaldson J; Ellis D; Moritz ML; Basu A; Morgan C; Vats AN; Erkan E; Shapiro R
    Transplantation; 2008 Dec; 86(12):1725-31. PubMed ID: 19104412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
    Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ
    Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Campath induction for kidney transplantation: report of 297 cases.
    Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
    Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
    Basu A; Ramkumar M; Tan HP; Khan A; McCauley J; Marcos A; Fung JJ; Starzl TE; Shapiro R
    Transplant Proc; 2005 Mar; 37(2):923-6. PubMed ID: 15848576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
    Tan HP; Kaczorowski D; Basu A; McCauley J; Marcos A; Donaldson J; Unruh M; Randhawa P; Zeevi A; Shapiro R
    Transplant Proc; 2005 Dec; 37(10):4235-40. PubMed ID: 16387087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation.
    Ciancio G; Gaynor JJ; Sageshima J; Guerra G; Zarak A; Roth D; Brown R; Kupin W; Chen L; Hanson L; Tueros L; Ruiz P; Livingstone AS; Burke GW
    Transplantation; 2011 Dec; 92(12):1348-57. PubMed ID: 22027927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial.
    Welberry Smith MP; Cherukuri A; Newstead CG; Lewington AJ; Ahmad N; Menon K; Pollard SG; Prasad P; Tibble S; Giddings E; Baker RJ
    Transplantation; 2013 Dec; 96(12):1082-8. PubMed ID: 24056618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
    Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients.
    Sung J; Barry JM; Jenkins R; Rozansky D; Iragorri S; Conlin M; Al-Uzri A
    Pediatr Transplant; 2013 Dec; 17(8):718-25. PubMed ID: 24164824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
    Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
    Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.